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Summary The interdisciplinary group of experts has 
compiled a clinical guidance for manifest dabigatran-
induced haemorrhage and envisaged invasive interven-
tions on patients under dabigatran. It recommends an 
escalation of treatment measures as summarized in a 
pocket guide (see electronic supplementary material 
online and insert in the print issue).
Keywords Thrombin time · Ccarin clotting time · Patient 
blood management · Haemodialysis · Prothrombincom-
plex concentrate · Recombinant factor VIIa
Management bei Dabigatran-induzierter Blutung – 
Expertenempfehlung
Zusammenfassung Die interdisziplinäre Experten-
gruppe hat einen klinischen Leitfaden für das Vorge-
hen bei manifester Dabigatran-induzierter Blutung 
und bei anstehenden invasiven Eingriffen bei Patienten 
unter Dabigatran zusammengestellt. Es wird ein eska-
lierendes Vorgehen vorgeschlagen und in einer Karte 
für die Manteltasche zusammengefasst (siehe “Electro-
nic supplementary material” online und Beilage in der 
Print-Ausgabe).
Schlüsselwörter Thrombinzeit  · Ecarin clotting time  · 
Patient Blood Management  · Hämodialyse  · Prothrom-
binkomplexkonzentrat · rekombinanter Faktor VIIa
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Introduction
Not least on account of demographic developments, the 
number of patients receiving oral anticoagulants is con-
stantly increasing [1]. Accordingly, in case of elective 
and semi-elective surgery, there is an increasing need 
for a perioperative risk benefit assessment of whether 
anticoagulation should be continued, discontinued, or 
“bridged” parenterally. In case of continued oral anti-
coagulation perioperatively and in case of acute surgery 
severe bleeding episodes may require rapid inhibition 
of the biological action of the anticoagulant (reversal). 
Emergency reversal may also be indicated after injuries 
and spontaneous non-surgical bleeding. Such measures 
should be taken in due consideration of the situation, i.e. 
depending on the severity of the (risk of ) haemorrhage, 
and balancing the risks of haemorrhage and thrombosis 
in view of the pre-existing indication for chronic anti-
coagulation. For Vitamin K antagonists, long-standing 
experience is available, although at a low level of scien-
tific evidence [2, 3]. Such experience and evidence on 
perioperative management and practical clinical bleed-
ing management is, however, still lacking for the new oral 
anticoagulants (NOACs; more recently also referred to 
as direct oral anticoagulants, DOACs). Dabigatran etexi-
late is the longest-standing NOAC registered for chronic 
application. Accordingly, the management of dabiga-
tran-induced haemorrhagic complications is currently a 
frequent clinical and interdisciplinary challenge.
Currently available expert statements permit only an 
incomplete insight into the complexity of the manage-
ment of dabigatran-induced haemorrhages, particularly 
in terms of the classification of haemorrhages according 
to acuity and severity, as well as the escalating indication 
for multi-modal therapies and the availability of therapy 
monitoring methods [4]. Therefore, the objective of the 
present interdisciplinary group of experts was to prepare 
recommendations for the management of dabigatran-
induced bleeding in the course of day-to-day clinical 
work. The resulting expert opinion reflects the medical 
knowledge, specific experience, evaluations and opin-
ions of the authors. As with all expert statements, each 
of these recommendations will have to be revised over 
time as new evidence and experience is gained. It should 
also be noted that use of the proposed recommendations 
will not guarantee therapeutic success or the absence of 
complications.
The present expert recommendation does not focus 
on presenting fundamental knowledge of the pharma-
cology of dabigatran and the research required for regis-
tration since such reviews are readily available [4–8]. For 
this reason, we merely recapitulate the facts relevant for 
prophylactic and therapeutic management of bleeding.
Background information on dabigatran
Action mechanism and pharmacology
Dabigatran is an oral, reversible direct thrombin inhibitor 
(DTI) that inhibits both free and fibrin-bound thrombin 
and thrombin-induced platelet aggregation [5, 6]. After 
adsorption, non-specific plasma esterases transform 
the inactive prodrug dabigatran etexilate into the active 
substance in both plasma and liver. Its mean terminal 
half-life has been stated to be 14–17 h but may be longer 
postoperatively [9]. As the drug is primarily eliminated 
by the kidneys, the half-life is significantly prolonged in 
patients with renal insufficiency [10]. For this reason, 
renal function should be monitored at regular intervals 
(e.g. twice a year) whenever dabigatran is used for long-
term therapy [11]. Contraindications against the use of 
dabigatran are a creatinine clearance < 30 ml/min, arti-
ficial heart valves, allergies, haemorrhages, liver disease 
affecting survival, spontaneous or pharmacologically 
induced impairment of haemostasis. A dose reduction of 
Pradaxa (from 2 × 150  mg to 2 × 110  mg per os or from 
220  mg to 150  mg per os) is indicated in patients with 
a creatinine clearance of 30–50  ml/min, concomitant 
administration of verapamil, in the presence of throm-
bopathy/thrombopenia, gastroesophageal reflux disease 
and in patients aged 80 years or older.
On account of its low tendency to bind to plasma pro-
teins, 62–68 % of the active substance can be eliminated 
by haemodialysis within 2–4 h [4]. It may be assumed that 
dabigatran can also be removed by haemofiltration and 
haemodiafiltration, though elimination times are likely 
to be longer (> 4 h).
Efficacy and approval
The randomised phase-III study RELY relevant for regu-
latory approval investigated the efficacy of dabigatran 
(2 × 110 mg/2 × 150 mg) vs. warfarin in preventing stroke 
and systemic embolism in 18,113 patients suffering from 
atrial fibrillation in combination with at least one addi-
tional risk factor for stroke [12], with the occurrence of 
stroke or embolism serving as primary endpoint. At the 
higher dosage level, the administration of dabigatran 
resulted in a significantly lower incidence of haemor-
ragic and ischaemic strokes as compared with warfarin, 
and the incidence of cardiovascular deaths was also sig-
nificantly lower. Dabigatran at 2 × 150 mg is so far the only 
direct oral anticoagulant causing a significant reduction 
of ischaemic strokes, which is numerically the most rele-
vant threat. However, no significant difference was found 
with regard to overall mortality. As far as patient safety 
was concerned, it should be noted that life-threatening 
haemorrhages, most importantly intracranial haemor-
rhage, occurred significantly less often in patients receiv-
ing dabigatran at either dosage level than in those treated 
with warfarin [12].
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the extent of the residual pharmacological coagulation 
inhibition caused by dabigatran [4]. In principle, this 
information could be obtained by means of the adapted 
thrombin time (e.g. the Hemoclot Test) or the ecarin 
clotting time (ECT). The determination of the adapted TT 
is based on the inhibition of a defined constant thrombin 
concentration in diluted plasma samples. On account of 
their linear dose-effect relation the adapted thrombin 
time and ECT permit, when calibrated in line with CE 
standards, a quantitative determination of the effect of 
dabigatran, whereas the correlation of these dabigatran-
sensitive tests with the clinical outcome parameters of 
haemorrhages is yet unclear. According to the manu-
facturer (SMPC, January 2013), a double or triple pro-
longation of the aPTT values dabigatran at trough level 
may ≥ 200  ng/ml in the Hemoclot Test may be associ-
ated with an increased bleeding risk in non-surgical 
patients. Most importantly, a threshold limit value for 
the Hemoclot Test, which predicts a low perioperative 
bleeding risk, has not yet been established.
Individual risk of thromboembolism 
and haemorrhage
Individual risks vary with the magnitude and nature of 
surgery (expositional risk factors) and individual (dispo-
sitional) risk factors. The bleeding risk of non-surgical 
patients can be assessed by means of the HAS-BLED 
Score, with a score of ≥ 3 being generally seen as indic-
ative of an increased risk of haemorrhage [16]. Post-
operative bleeding risk and possible strategies to control 
bleeding will also depend on the experience of the medi-
cal care personnel and on locally available resources.
One well-established approach to the stratification of 
the risks of thromboembolism and stroke is the use of the 
CHADS2 Score and the CHA2DS2-VASc Score [17]. In cases 





(≤ 4) and a negative history concerning a thromboem-
bolic event anticoagulation with dabigatran may be dis-
continued for up to 1 week without causing a clinically 
relevant increase in the thromboembolism rate.
With pending indications for the use of dabigatran in 
patients with deep vein thrombosis or pulmonary embo-
lism [18, 19], bleeding complications may and will occur 
in this cohort as well. Nevertheless, the longer treatment 
and the higher dosage will, in general, always be applied 
to patients with atrial fibrillation. Therefore, the risks of 
haemorrhage may possibly be extrapolated to these new 
indications.
Management of bleeding in patients receiving 
dabigatran
Strategies recommended for the management of mani-
fest bleeding in patients receiving dabigatran have been 
summarised in Fig. 1.
In Austria, dabigatran has been approved under the 
trade name Pradaxa for primary prevention of venous 
thromboembolic events in adult patients following elec-
tive surgery for hip or knee joint replacement at a dosage 
level of 220 mg 1x a day or 150 mg 1x a day, as well as for 
the prevention of strokes or embolisms in non-valvular 
atrial fibrillation at a level of 150 mg 2x a day or 110 mg 2x 
a day. Dabigatran is recommended as a ‘first-line’ ther-
apy for this chronic indication [13].
Coagulation tests
No laboratory analyses are required for routine monitor-
ing during dabigatran therapy [6]. Under certain clinical 
conditions, however, it may be advisable to test for the 
new anticoagulants, for instance in cases of suspected 
accidental overdosing, acute bleeding complications, 
invasive emergency interventions, drug interaction, 
renal insufficiency, critically ill patients, advanced age 
and to check compliance.
Routine coagulation tests
Depending on the dosage administered and the time 
between the last administration and blood sampling, 
dabigatran may significantly affect the results of all con-
ventional coagulation tests [14]. Accordingly, the diag-
nostic acuity of routine coagulation tests is impaired 
when preoperative patients treated with dabigatran are 
tested for other hereditary or acquired coagulopathies. 
Prolonged routine lab tests will not provide specific and 
quantitative information on the causation or level of 
dabigatran and could also be due to other haemostatic 
disorders or substances [14].
A combination of a highly pathological prothrombin 
time (INR > 2) and a highly pathological activated par-
tial thromboplastin time (aPTT > 90 s) at the trough level 
may suggest (but cannot prove) possible overdosing of 
dabigatran [15]. According to the manufacturer (SMPC, 
January 2013), a double or triple prolongation of the 
aPTT values dabigatran at trough level may be associated 
with an increased bleeding risk. The thrombin time (TT) 
is prolonged even at low dabigatran plasma levels, thus 
a normal TT can be assumed to rule out a clinically rel-
evant dabigatran level.
The least influence on routine coagulation tests can be 
expected at the trough level of dabigatran 12 h after the 
last or immediately before the next administration. To 
avoid misinterpretations and possibly wrong therapeu-
tic decisions it is therefore imperative, when requesting 
routine coagulation tests for patients treated with dabi-
gatran, to inform the laboratory of the last time the drug 
was administered.
Dabigatran-sensitive tests
Dabigatran-sensitive coagulation tests performed 
shortly before surgery could best provide information on 
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merular filtration rate eGFR using the MDRD formula) 
may be useful to estimate the risk of dabigatran accumu-
lation. Before resuming dabigatran therapy in patients 
with renal insufficiency care should be taken to modify, 
if necessary, the dosage and/or review the indication for 
dabigatran.
In the case of spontaneous minor bleeding it does 
not appear imperative to routinely perform laboratory 
coagulation tests. Excessively prolonged coagulation 
times may, however, be seen as an indicator of possible 
overdosing requiring further diagnostic (dabigatran level 
determination, exploration of other coagulopathies) and 
therapeutic action (review of dabigatran dosage and its 
indication).
Strategies not recommended
On the basis of a risk/benefit assessment in cases of mild 
bleeding it is not advisable to use coagulation factor con-
centrates in an attempt to reverse dabigatran action. The 
use of tranexamic acid for mild haemorrhages does not 
appear useful in the absence of any association with the 
pathomechanism of dabigatran-induced bleeding.
In view of the fact that mild bleeding complications 
can usually be managed by other means, general mea-
sures to reduce dabigatran resorption and stimulating 
elimination are not recommended.
Severe bleeding
 Definition 
Severe bleeding is defined as haemorrhages that require 
transfusion but, in terms of their haemodynamic rel-
evance, do not appear to require catecholamines 




The term mild bleeding (e.g. superficial bleeding, diver-
ticular bleeding) describes haemorrhages that do not 
require transfusions, are haemodynamically irrelevant 
and can be staunched easily.
Basic measures
Basic measures comprise general clinical observation 
of the haemorrhagic patient including haemodynamic 
monitoring and local haemostasis. The latter can be 
achieved by such means as mechanical compression or 
sclerotherapy on condition that the area of bleeding is 
accessible. Other basic measures are the avoidance of 
arterial pressure peaks, hypothermia, etc.
Administration of dabigatran
Until haemostasis has been achieved, patients may 
require skipping of one or more dosages of dabigatran—
all on condition that the increased risk of thrombosis 
does not outweigh the current risk of bleeding. If anti-
coagulation with dabigatran has been discontinued, it 
can be resumed within 72 h once haemostasis has been 
achieved, in particular if the relapse risk is considered to 
be low and that of thromboembolism high.
Laboratory tests
A blood count analysis (including a platelet count) or, if 
the same is not readily available, the determination of the 
haematocrit/haemoglobin values by blood gas analysis 
may be used to exclude haemorrhages requiring blood 
transfusion. A renal function test (determination of cre-
atinine clearance by the Cockroft-Gault formula, glo-
Fig. 1 Management of 
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without further benefit for the patient, compound the 
manifest risk of haemorrhage with an additional risk of a 
thromboembolic event.
Life-threatening or organ-threatening bleeding
Definition  
The borderline between massive and life-threatening 
haemorrhages is blurred but can be arbitrarily defined 
by the need for transfusion with ≥ 4 erythrocyte concen-
trates and the administration of exogenous catechol-
amins (noradrenalin, adrenalin, dobutamine) for the 
purpose of haemodynamic stabilisation. Diagnosis of 
an organ-threatening haemorrhage depends also on the 
localisation of the lesion, e.g intracerebral, intraspinal or 
intraocular and the risk of the intervention(s) to achieve 
local haemostasis.
Basic measures, administration of dabigatran 
and laboratory tests
Cases of life-threatening or organ-threatening bleeding 
should be managed in the same way as severe bleed-
ing (see severe bleeding section above); in addition, the 
feasibility of emergency measures to offset dabigatran 
action (emergency reversal) should be considered. In the 
absence of clinical evidence for emergency reversal of 
dabigatran only few experimental studies and pharma-
cological data are available and suggest that the action of 
dabigatran might, at least partially, be offset by activated 
prothrombin complex concentrate (e.g. factor eight 
bypassing activity FEIBA) or recombinant factor VIIa 
[23–28]. To date no dose-finding studies have been pub-
lished for this indication. Should reversal be planned, 
an initial dose of at least 25  U/kg BW FEIBA or at least 
50 µg/kg BW rFVIIa (NovoSeven) could be considered, 
possibly with a repeated administration. Considering the 
strong increase in thrombin generation induced by these 
activated coagulation factor concentrates they should 
be used only after careful benefit/risk assessment. Cost-
effectiveness of FEIBA and rFVIIa for the reversal of dabi-
gatran has not yet been proven. Furthermore, FEIBA and 
rVIIa, or experience with their use, are not available in all 
hospitals.
Conventional prothrombin complex concentrate 
(PCC) (Beriplex 50  U/kg BW) stopped bleeding in an 
animal experiment [26] but heparin-free PCC (Cofact 50 
U/kg BW) could not reverse clotting times in six volun-
teers after 2.5 days dabigatran intake [27]. Clinical out-
come parameters of bleeding were not assessed in this 
volunteer trial [27]. PCC is listed in monodisciplinary 
recommendations as a reversing agent [7]. National 
data recorded by the NOAC Line (www.oegari.at) sug-
gest favourable results with PCC, so that an attempted 
reversal with PCC may be seen as a possible therapeu-
tical option if bleeding is deemed life-threatening or 
organ-threatening.
Basic measures
In the case of heavy bleeding (e.g. psoas muscle bleed-
ing) it is recommended to control symptoms by individu-
alised volume replacement for the purpose of achieving 
haemodynamic stabilisation and to transfuse erythro-
cyte concentrates on the basis of individualised transfu-
sion triggers. Mostly the transfusion trigger should not 
exceed 9 g/dl nor be lower than 7 g/dl [20]. Depending 
on the extent of bleeding, invasive haemostatic methods, 
e.g. surgical or radiologic/endovascular interventions, 
should be considered. As a basic principle, it is advis-
able to avoid hypothermia, acidosis and hypocalcaemia. 
Correction of secondarily acquired coagulopathies (e.g. 
hyperfibrinolysis by antifibrinolytics, factor deficits by 
coagulation factor concentrates) may be undertaken in 
line with current trauma guidelines [21, 22].
Administration of dabigatran
In the case of severe bleeding dabigatran should be dis-
continued until haemostasis has been achieved; once 
this is the case, anticoagulation with dabigatran can be 
resumed with an appropriate safety window of 3 days to 
2 weeks.
In the case of recent oral dabigatran intake (within 
the last 2 h) enteral administration of activated coal 
(1 g/kg BW) is recommended, which will bind the sub-
stance and reduce resorption [23]. Moreover, dabigatran 
can be eliminated by haemodialysis.
Laboratory tests
A blood count analysis (including a platelet count) or, if 
the same is not readily available, the determination of the 
haematocrit/haemoglobin values by blood gas analysis 
is recommended, since it will allow targeted erythrocyte 
transfusion and avoid transfusion in excess of the indi-
vidual transfusion triggers.
In the case of severe bleeding requiring transfusion 
it is recommended to perform routine coagulation tests 
(with blood samples preferably at dabigatran trough 
level) in order to rule out (not yet) evaluated hereditary 
or acquired coagulation disorders if the bleeding was 
not (or not exclusively) caused by dabigatran. Prolonged 
thrombin times may lead to evaluation of dabigatran lev-
els (e.g. Hemoclot Test).
A renal function test (eGFR, creatinine clearance) 
will permit conclusions regarding possible accumula-
tions that will help adapt the dosage once haemostasis 
has been achieved. The indication for dabigatran therapy 
should be checked before administration is resumed.
Strategies not recommended
In the case of severe bleeding that is not life-threatening 
and does not jeopardise an organ function, emergency 
dabigatran reversal by means of coagulation factor 
concentrates is not recommended because this might, 
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surgery and the early postoperative phase is seen as an 
important factor of patient safety. Accordingly, discon-
tinuation of vitamin K antagonists and, where neces-
sary, bridging with low-molecular-weight heparins is 
recommended [2, 3]. Similarly, dabigatran may be dis-
continued. Whether bridging with heparins should be 
performed in the case of NOACs is still controversial. The 
authors of the present recommendations do not recom-
mend bridging when NOACs are discontinued for the 
periods stipulated in the MAA documentation to prevent 
a possible increase in perioperative bleeding risk. How-
ever, if the thromboembolic risk is higher (CHADS2-Vasc 
Score ≥ 4) and surgery requires discontinuation of dabi-
gatran for more than 5 days, a bridging therapy with low-
molecular-weight heparin may be an option [11].
At what time dabigatran should be discontinued pre-
operatively will depend on the patient’s current renal 
function [31]. In patients with a normal renal elimination 
facing a low-risk intervention a 2-day interval may be 
sufficient to preclude a clinically relevant residual effect 
of dabigatran during surgery. In the case of patients 
with a reduced renal elimination (creatinine clearance 
< 50  ml/min) and a high-risk intervention dabigatran 
should be suspended for at least 4 days to prevent the 
intraoperative risk of residual anticoagulation.
Particularly in the case of major interventions the the-
atre staff should make full use of available measures to 
ensure effective haemostasis and thus avoid excessive 
blood transfusions. The ward staff should be made fully 
aware of the risk of postoperative complications (haem-
orrhages or thromboses) to ensure rapid recognition and 
correction.
Laboratory    tests
Pre-operative renal function tests (creatinine clearance 
according to the Cockroft-Gault formula or calculating 
Measures not recommended
In view of the limited efficacy of fresh frozen plasma (FFP) 
to correct perioperative bleeding [29] and abnormal lab-
oratory coagulation test results [30] the administration of 
FFP to reverse dabigatran-induced haemorrhages can-
not be recommended.
Perioperative management of dabigatran-treated 
patients
Recommended strategies are summarised in Fig. 2.
Elective interventions
Surgical interventions should be classified in terms of 
their bleeding risk.
Minor interventions
In the case of minor interventions with a low bleeding risk 
it is recommended to continue administration of vitamin 
K antagonists [2, 3]. Analogously, dabigatran can also be 
continued in such cases [3]. During the intervention the 
theatre staff should make full use of available measures 
to ensure effective haemostasis and thus avoid excessive 
blood transfusions. The ward staff should be made fully 
aware of the risk of postoperative complications (haem-
orrhages) to ensure rapid recognition and correction.
Major interventions
In major interventions the bleeding risk is either due to 
the extent of foreseeable haemorrhage or its critical loca-
tion (e.g. intracranial). Normal coagulation during major 
Fig. 2 Management of 




  7271 3 Management of dabigatran-induced bleeding: expert statement
of study data, locoregional anaesthesia or the neur-
axial catheter technique should not be used in patients 
for whom a rapid resumption of the administration of 
therapeutic doses of dabigatran (2 × 150 mg or 2 × 110 mg 
Praxada per day) has been envisaged.
Acute and urgent major interventions (within 24 h)
Administration of  dabigatran
In the case of acute or urgent (semi-elective) major sur-
gery with a relevant risk of bleeding (e.g. fractures near 
the hip, revision of septic joints, urgent tumour surgery) 
it is imperative to establish exactly when dabigatran was 
last administered: If the time interval recommended for 
elective major surgery cannot be respected on account 
of the urgency of the intervention, dabigatran therapy 
should at least be interrupted as soon as the indication 
for surgery has been established. If dabigatran was last 
given within the last 1 or 2 h, reduction of resorption by 
means of oral activated coal may be attempted. Prior to 
high-bleeding-risk interventions it might be reasonable 
to reduce dabigatran by means of haemodialysis for > 4 h.
Basic  measures 
Patient monitoring should comply with the measures 
outlined in the severe bleeding section above.
Symptomatic treatment of slight, massive, life-threat-
ening and organ-threatening haemorrhages should be 
in line with the severe bleeding and life-threatening or 
organ-threatening bleeding section above.
Administration of coagulation factor concentrates 
should only be considered individually in the case of 
massive bleeding.
Laboratory  tests
TT can be used to determine whether a residual dabiga-
tran effect is still to be expected immediately before or 
in the course of an urgent or acute surgical intervention. 
Normal TT values may exclude the presence of a clini-
cally relevant residual dabigatran effect. It is advisable 
to measure TT at two points in time to assess possible 
variations in the findings. If the TT is prolonged, a dab-
igatran-sensitive test should be performed as outlined in 
the mild bleeding section above: adapted thrombin time 
(e.g. Hemoclot Test) or ecarin clotting time (ECT).
Particularly in the case of massive bleeding repeated 
blood counts are recommended to ensure targeted 
transfusion. Routine coagulation tests, and possibly also 
complementary rotational thromboelastometry/throm-
boelastography (especially for the diagnosis of hyper-
fibrinolysis) should be performed repeatedly to permit 
targeted correction of (especially) secondarily acquired 
coagulopathies [3, 22, 35].
the glomerular filtration rate according to the MDRD for-
mula) help determine the necessary interval before dis-
continuation of dabigatran administration.
Pre-operative blood counts or haemoglobin/haema-
tocrit assays may detect the presence of anaemia, and 
a subsequent differential diagnosis and correction may 
enhance tolerance to perioperative bleeding [3]. This rec-
ommendation is in line with the concept of patient blood 
management [32]. An intra-operative and post-operative 
blood count analysis (including a platelet count) or, if 
the same is not readily available, the determination of 
haemoglobin/haematocrit values by means of blood gas 
analysis is recommended since it may serve as an indi-
cation for erythrocyte transfusion and can help avoid 
transfusions as soon as the individual transfusion trigger 
is exceeded.
The success of discontinuing vitamin K antagonists 
can be checked by means of the target value of INR (pre-
operatively mostly < 1.4). Analogously, it would be desir-
able to obtain direct evidence that a safe plasma level 
has been reached or that the biological anticoagulatory 
effects of dabigatran have been eliminated. A dabiga-
tran-sensitive coagulation test shortly prior to surgery 
might provide information on the extent of residual 
pharmacological anticoagulation [4]. The residual effect 
of dabigatran cannot be quantified by means of routine 
coagulation tests (global tests such as aPTT, PT, INR).
Strategies  not recommended
Prophylactic administration of coagulation factor con-
centrates is not recommended for elective interven-
tions since the operative trauma would compound the 
pre-existing risks of thromboembolism and acute-phase 
reaction with yet another prothrombotic stimulus in 
the form of the concentrates. Our recommendation, as 
described above in the context of acute bleeding, is to 
consider the administration of coagulation factor con-
centrates only in cases of severe intra-operative or post-
operative haemorrhage.
Elective  interventions under regional anaesthesia
Dabigatran for postoperative thrombosis prevention 
has only been approved for elective hip and knee joint 
replacement. In these cases the intervention may be 
performed under neuraxial regional anaesthesia: The 
epidural catheter is put in place prior to starting the 
postoperative administration of the prophylactic dose 
of dabigatran (110  mg Praxada 2–4  h postoperatively, 
followed by 1 × 220  mm Praxada per day). Dabigatran 
should only be administered after removal of the cath-
eter, in the interest of patient safety with a delay of at least 
2  h. According to the current recommendations based 
on pharmacokinetics the catheter may also be removed 
after a dabigatran withdrawal interval of 26  h, and the 
next dose of dabigatran should be given, at the earliest, 
4–6 h after removal of the catheter [33, 34]. In the absence 
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